Navigation Links
Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
Date:1/13/2014

REDWOOD CITY, Calif., Jan. 13, 2014 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced it has appointed Liam Burns to the position of Vice President, Sales and Marketing.

"Liam has been working with Cardica for several years, and has helped us to establish relationships with key U.S. surgeons interested in the MicroCutter XCHANGE™ 30," said Bernard A. Hausen, M.D., Ph.D., president and CEO of Cardica. "As we begin our selective introduction of the MicroCutter XCHANGE 30 to key accounts in the US, and seek to expand our presence in the European Union, Liam's expertise in product introductions and his network of relationships with surgeons will be instrumental in the commercialization of the MicroCutter XCHANGE 30."

Mr. Burns brings more than 20 years of medical device sales and marketing expertise to Cardica. Most recently, he served as president of a strategic marketing and sales practice he founded to help healthcare and life science companies accelerate product sales and market growth through executive leadership development, effective sales and marketing programs and key business processes. Earlier in his career, he served as vice president of marketing at Power Medical Interventions, Inc. leading a global team responsible for all aspects of marketing, sales, clinical affairs and physician education. Previously, he served in escalating roles at Johnson & Johnson – Ethicon, Inc., most recently as group marketing director for biosurgicals. Prior to his experience in the medical device industry, he served as a lieutenant in the United States Navy. He received an MBA from Case Western Reserve University, and a bachelors of arts in economics from the College of the Holy Cross. He is the author of numerous healthcare publications.

About Cardica 
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its MicroCutter XCHANGE™ 30, a cartridge-based surgical stapling device with a five-millimeter shaft diameter, for use in a variety of gastrointestinal procedures and appendectomies in the United States and a wide range of surgical procedures in Europe. Cardica is developing the Cardica® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device with an eight-millimeter shaft to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 45 product requires 510(k) review and CE Mark and is not yet commercially available in the U.S. or internationally. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 47,700 units throughout the world.

Forward-Looking Statements
The statement in this press release regarding Cardica's intent to implement a selective commercial launch of the XCHANGE 30 in the United States in the months ahead is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including: that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons; and that Cardica may not have sufficient funds to commercialize the XCHANGE 30, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, under the caption "Risk Factors." Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.

 


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Cardica Updates Enrollment Progress In European Clinical Trial
10. Cardica Announces Proposed Public Offering of Common Stock
11. Cardica Prices Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):